PMID- 33314408
OWN - NLM
STAT- MEDLINE
DCOM- 20211006
LR  - 20240226
IS  - 1095-8355 (Electronic)
IS  - 1065-6995 (Linking)
VI  - 45
IP  - 3
DP  - 2021 Mar
TI  - H19/miR-107/HMGB1 axis sensitizes laryngeal squamous cell carcinoma to cisplatin 
      by suppressing autophagy in vitro and in vivo.
PG  - 674-685
LID - 10.1002/cbin.11520 [doi]
AB  - Laryngeal squamous cell carcinoma (LSCC) is the most common malignant tumor, 
      which occurs in the head and neck. Current treatments for LSCC are all largely 
      weakened by increasing drug resistance. Our study aimed to investigate the 
      effects of long noncoding RNA (lncRNA) H19 on drug resistance in LSCC. In our 
      study, we found that the level of H19 was sharply upregulated in LSCC tissues and 
      drug-resistant cells compared with the control. Besides, the expression of 
      high-mobility group B1 (HMGB1) was elevated, and microRNA107 (miR-107) was 
      suppressed in drug-resistant cells compared with the control. Further study 
      revealed that the interference of H19 by short hairpin RNA (shRNA) effectively 
      suppressed high autophagy level and obvious drug resistance in drug-resistant 
      cells. Besides that, miR-107 was predicted as a target of H19 and inhibiting 
      effects of H19 shRNA on autophagy and drug resistance were both reversed by 
      miR-107 inhibitor. Moreover, HMGB1 was predicted as a target of miR-107 in LSCC 
      cells and knockdown of HMGB1 was able to suppress autophagy and drug resistance 
      in LSCC cells. In addition, our investigation demonstrated that H19 shRNA exerted 
      an inhibiting effect on autophagy and drug resistance by downregulating HMGB1 
      by targeting miR-107. Finally, the in vivo experiment revealed that LV-H19 shRNA 
      strongly suppressed drug resistance compared with the usage of cisplatin 
      individually. Taken together, our research indicated an H19-miR-107-HMGB1 axis in 
      regulating the autophagy-induced drug resistance in LSCC in vitro and in vivo, 
      providing novel targets for molecular-targeted therapy and broadening the 
      research for LSCC.
CI  - (c) 2020 International Federation for Cell Biology.
FAU - Chen, Liwei
AU  - Chen L
AD  - Department of Otolaryngology Head and Neck Surgery, Hainan Branch of Chinese PLA 
      General Hospital, Sanya, Hainan, China.
AD  - Department of Otolaryngology Head and Neck Surgery, Chinese PLA General Hospital, 
      Beijing, China.
FAU - Xu, Zhijian
AU  - Xu Z
AD  - Department of Cancer Prevention, Cancer Hospital, Chinese Academy of Medical 
      Sciences & Peking Union Medical College, Beijing, China.
FAU - Zhao, Jiandong
AU  - Zhao J
AD  - Department of Otolaryngology Head and Neck Surgery, Chinese PLA General Hospital, 
      Beijing, China.
FAU - Zhai, Xingyou
AU  - Zhai X
AD  - Department of Otolaryngology Head and Neck Surgery, Hainan Branch of Chinese PLA 
      General Hospital, Sanya, Hainan, China.
FAU - Li, Jianhui
AU  - Li J
AD  - Department of Otolaryngology Head and Neck Surgery, Hainan Branch of Chinese PLA 
      General Hospital, Sanya, Hainan, China.
FAU - Zhang, Yongxia
AU  - Zhang Y
AD  - Department of Otolaryngology Head and Neck Surgery, Chinese PLA General Hospital, 
      Beijing, China.
FAU - Zong, Liang
AU  - Zong L
AD  - Department of Otolaryngology Head and Neck Surgery, Chinese PLA General Hospital, 
      Beijing, China.
FAU - Peng, Honghua
AU  - Peng H
AD  - Department of Otolaryngology, Liangxiang Hospital, Beijing, China.
FAU - Qi, Jixia
AU  - Qi J
AD  - Department of Otolaryngology Head and Neck Surgery, Weifang Medical University, 
      Weifang, Shandong, China.
FAU - Kong, Xinru
AU  - Kong X
AD  - Department of Otolaryngology Head and Neck Surgery, Weifang Medical University, 
      Weifang, Shandong, China.
FAU - Fang, Zhongju
AU  - Fang Z
AD  - Department of Otolaryngology Head and Neck Surgery, Weifang Medical University, 
      Weifang, Shandong, China.
FAU - Liu, Mingbo
AU  - Liu M
AUID- ORCID: 0000-0002-6279-8551
AD  - Department of Otolaryngology Head and Neck Surgery, Hainan Branch of Chinese PLA 
      General Hospital, Sanya, Hainan, China.
AD  - Department of Otolaryngology Head and Neck Surgery, Chinese PLA General Hospital, 
      Beijing, China.
LA  - eng
PT  - Journal Article
DEP - 20201231
PL  - England
TA  - Cell Biol Int
JT  - Cell biology international
JID - 9307129
RN  - 0 (H19 long non-coding RNA)
RN  - 0 (HMGB1 Protein)
RN  - 0 (MIRN107 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (RNA, Long Noncoding)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Aged
MH  - Animals
MH  - *Autophagy/genetics
MH  - Base Sequence
MH  - Cell Line, Tumor
MH  - Cisplatin/*pharmacology
MH  - Down-Regulation/drug effects/genetics
MH  - Drug Resistance, Neoplasm/drug effects/genetics
MH  - Female
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Gene Knockdown Techniques
MH  - HMGB1 Protein/*metabolism
MH  - Humans
MH  - Laryngeal Neoplasms/*genetics/*pathology
MH  - Male
MH  - Mice, Nude
MH  - MicroRNAs/genetics/*metabolism
MH  - Middle Aged
MH  - RNA, Long Noncoding/genetics/*metabolism
MH  - Mice
OTO - NOTNLM
OT  - H19
OT  - HMGB1
OT  - LSCC
OT  - autophagy
OT  - drug resistance
OT  - miR-107
EDAT- 2020/12/15 06:00
MHDA- 2021/10/07 06:00
CRDT- 2020/12/14 11:11
PHST- 2020/10/12 00:00 [revised]
PHST- 2020/06/18 00:00 [received]
PHST- 2020/12/06 00:00 [accepted]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2021/10/07 06:00 [medline]
PHST- 2020/12/14 11:11 [entrez]
AID - 10.1002/cbin.11520 [doi]
PST - ppublish
SO  - Cell Biol Int. 2021 Mar;45(3):674-685. doi: 10.1002/cbin.11520. Epub 2020 Dec 31.